Key Highlights
- Strategic Agreement: Charles River Laboratories grants Aitia access to Logica™, an AI-powered drug discovery platform, focusing on neurodegenerative diseases and oncology.
- Impact on Neurodegenerative Diseases: Aitia aims to develop treatments for Alzheimer’s, Parkinson’s, Huntington’s diseases, addressing a significant global health burden.
- Oncology Research Advancements: The partnership will also focus on prostate cancer and multiple myeloma, employing Digital Twins technology for targeted drug development.
Source: Business Wire
Notable Quotes
- “Unraveling the complex genetic and molecular circuitry of neurodegenerative disorders is critical to the discovery of treatments that significantly slow or reverse these devastating diseases,” – Colin Hill, CEO and Co-founder at Aitia
- “Combining Aitia’s Digital Twins with Logica’s next-generation solution stands to transform the discovery and development of novel therapeutics for neurological diseases and oncology,” – Professor Julie Frearson, Ph.D., Corporate Senior Vice President and Chief Scientific Officer at Charles River
- “Logica has optimized drug discovery,” – Emilio Cordova, Executive Director at Logica
SoH's Take
This partnership marks a pivotal moment in drug discovery. Charles River’s provision of Logica to Aitia underlines the growing emphasis on AI and Digital Twins in accelerating the development of effective therapies for complex diseases like Alzheimer’s and various cancers. The collaboration’s focus on neurodegenerative diseases and oncology is particularly noteworthy, given the rising global incidence of these conditions and the urgent need for innovative treatments. By combining Charles River’s extensive experience in preclinical research with Aitia’s cutting-edge Causal AI and Digital Twins technology, this alliance promises to unlock new possibilities in the realm of precision medicine, potentially leading to more targeted, effective treatments. This collaboration not only signifies a step forward in tackling some of the most challenging health issues of our time but also exemplifies the power of strategic partnerships in advancing medical science.
